| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9343(99)00053-4 |
| P698 | PubMed publication ID | 10225244 |
| P2093 | author name string | D Alarcón-Segovia | |
| A R Cabral | |||
| C Drenkard | |||
| J Cabiedes | |||
| A R Villa | |||
| L Gómez-Pacheco | |||
| P2860 | cites work | Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease | Q68091809 |
| Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus | Q68153286 | ||
| The presence of antiphospholipid antibodies in acute myocardial infarction | Q70803300 | ||
| Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus | Q71170843 | ||
| Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome | Q71334714 | ||
| Binding of beta 2-glycoprotein I to platelets: effect of adenylate cyclase activity | Q71417830 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome. Clinical relevance in neuropsychiatric systemic lupus erythematosus | Q73685453 | ||
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus | Q28290536 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients | Q33438663 | ||
| Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome | Q33488745 | ||
| Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects | Q33490868 | ||
| The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays | Q33497875 | ||
| Anticardiolipin antibodies and beta 2-glycoprotein I. | Q40391332 | ||
| Antiphospholipid antibodies and thrombosis: assessment of the potential risk for thrombosis | Q41066168 | ||
| Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface | Q42084495 | ||
| Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. | Q51578946 | ||
| Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus | Q57437612 | ||
| Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus | Q68008000 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| P433 | issue | 4 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| thrombosis | Q261327 | ||
| P304 | page(s) | 417-423 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients | |
| P478 | volume | 106 |
| Q73873107 | Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome |
| Q78594359 | Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy |
| Q37045158 | Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview |
| Q36844544 | Antiphospholipid syndrome: laboratory testing and diagnostic strategies |
| Q35114246 | Antiphospholipid syndrome: why and how should we make the diagnosis? |
| Q35849691 | Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q34990076 | Catastrophic antiphospholipid syndrome in the intensive care unit |
| Q28196276 | Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers |
| Q58854434 | Lymphomes malins et syndrome des antiphospholipides non simultanés : quatre observations |
| Q33344207 | Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies |
| Q52957322 | Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma. |
| Q55547645 | Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. |
| Q73672348 | [Aspirin and antiphospholipid syndrome] |
Search more.